Subfamily E simian adenoviruses A1302, A1320, A1331 and A1337 and uses thereof

Patent metadata

Field	Value
Publication number	US-9217159-B2
Application number	US-201313896722-A
Country	US
Kind code	B2
Filing date	May 17, 2013
Priority date	May 18, 2012
Publication date	Dec 22, 2015
Grant date	Dec 22, 2015

Abstract

Recombinant vectors comprise simian adenovirus A1302 (SAdV-A1302, SAdV-A1320, SAdV-A1331, and/or SAdV-A1337 sequences and a heterologous gene under the control of regulatory sequences. A cell line which expresses simian adenovirus SAdV-A1302, SAdV-A1320, SAdV-A1331, and/or SAdV-A1337 gene(s) is also disclosed. Methods of using the vectors and cell lines are provided.

First claim

The invention claimed is:

1. An adenovirus having a capsid comprising a hexon protein, a penton protein, and a fiber protein, wherein said hexon protein is the hexon protein of SAdV-A1337 with the amino acids 1 to 931 of SEQ ID NO: 86, and wherein said penton protein is the penton protein of SAdV-A1337 with the amino acids 1 to 532 of SEQ ID NO: 81,
said capsid encapsidating a heterologous nucleic acid comprising a gene operably linked to expression control sequences which direct transcription, translation, and/or expression thereof in a host cell.

2. The adenovirus according to claim 1 , further comprising a 5′ and a 3′ adenovirus cis-element necessary for replication and encapsidation.

3. The adenovirus according to claim 1 , wherein said adenovirus lacks all or a part of the E1 gene.

4. The adenovirus according to claim 3 , wherein said adenovirus is replication—defective.

5. The adenovirus according to claim 1 , wherein said capsid is a hybrid capsid.

6. The adenovirus according to claim 5 , wherein said hybrid capsid further comprises a capsid protein from an adenovirus selected from SAdV-A 1302, SAdV-A 1320, and SAdV-A 1331.

7. A composition comprising an adenovirus according to claim 1 in a pharmaceutically acceptable carrier.

8. A composition comprising the adenovirus according to claim 1 , said adenovirus further comprising at least one simian adenovirus protein selected from the group consisting of:
E1a, SEQ ID NO: 103;
E1b, small T/19K, SEQ ID NO: 78;
E1b, large T/55K, SEQ ID NO: 98;
52/55D, SEQ ID NO: 79;
Ma, SEQ ID NO: 80;
VII, SEQ ID NO: 82;
V, SEQ ID NO: 83;
pX, SEQ ID NO: 84;
VI, SEQ ID NO: 85;
100 kD, SEQ ID NO: 88;
22 kD, SEQ ID NO: 99;
VIII, SEQ ID NO: 89;
E3/12.5 K, SEQ ID NO: 90;
CR1-alpha SEQ ID NO: 100;
gp19K, SEQ ID NO: 91;
CR1-beta, SEQ ID NO: 92;
CR1-gamma, SEQ ID NO: 93;
CR1-delta, SEQ ID NO: 94;
RID-beta, SEQ ID NO: 95; and
E3/14.7K, SEQ ID NO: 101.

9. An adenovirus having a capsid comprising a hexon protein, a penton protein, and a fiber protein, wherein said hexon protein is the hexon protein of SAdV-A1337 with the amino acids 1 to 931 of SEQ ID NO: 86, and wherein said fiber protein is the fiber protein of SAdV-A1337 with the amino acids 1 to 490 of SEQ ID NO: 96,
said capsid encapsidating a heterologous nucleic acid comprising a gene operably linked to expression control sequences which direct transcription, translation, and/or expression thereof in a host cell.

10. The adenovirus according to claim 9 , wherein said penton protein is the penton protein of SAdV-A1337 with the amino acids 1 to 532 of SEQ ID NO: 81.

11. The adenovirus according to claim 9 , further comprising a 5′ and a 3′ adenovirus cis-element necessary for replication and encapsidation.

12. The adenovirus according to claim 9 , wherein said adenovirus lacks all or a part of the E1 gene.

13. The adenovirus according to claim 12 , wherein said adenovirus is replication—defective.

14. The adenovirus according to claim 9 , wherein said capsid is a hybrid capsid.

15. The adenovirus according to claim 14 , wherein said hybrid capsid further comprises a capsid protein from an adenovirus selected from SAdV-A1302, SAdV-A1320, and SAdV-A1331.

16. A composition comprising an adenovirus according to claim 9 in a pharmaceutically acceptable carrier.

17. A composition comprising the adenovirus according to claim 9 , said adenovirus further comprising at least one simian adenovirus protein selected from the group consisting of:
E1a, SEQ ID NO: 103;
E1b, small T/19K, SEQ ID NO: 78;
E1b, large T/55K, SEQ ID NO: 98;
52/55D, SEQ ID NO: 79;
Ma, SEQ ID NO: 80;
VII, SEQ ID NO: 82;
V, SEQ ID NO: 83;
pX, SEQ ID NO: 84;
VI, SEQ ID NO: 85;
100 kD, SEQ ID NO: 88;
22 kD, SEQ ID NO: 99;
VIII, SEQ ID NO: 89;
E3/12.5 K, SEQ ID NO: 90;
CR1-alpha SEQ ID NO: 100;
gp19K, SEQ ID NO: 91;
CR1-beta, SEQ ID NO: 92;
CR1-gamma, SEQ ID NO: 93;
CR1-delta, SEQ ID NO: 94;
RID-beta, SEQ ID NO: 95; and
E3/14.7K, SEQ ID NO: 101.

Assignees

• Univ Pennsylvania

Inventors

• Roy Soumitra
• Wilson James M

Classifications

• A61K35/761

  Adenovirus · CPC title

• C12N2710/10342

  virus or viral particle as vehicle, e.g. encapsulating small organic molecule · CPC title

• C12N2710/10334

  Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein · CPC title

• C12N2710/10321

  Viruses as such, e.g. new isolates, mutants or their genomic sequences · CPC title

• C07K14/005

  from viruses · CPC title